Osaka, Japan

Kana Kurahashi

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 6.8

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018-2019

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Kana Kurahashi

Introduction

Kana Kurahashi is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with specific inhibitory activities. With a total of 3 patents to her name, her work continues to impact the industry.

Latest Patents

Kana's latest patents include a non-aromatic heterocyclic derivative that exhibits MGAT2 inhibitory activity. This invention relates to a compound represented by a specific formula, which includes various components such as aromatic carbocycles and pharmaceutically acceptable salts. Another notable patent is for a 9-membered fused ring derivative, aimed at providing novel compounds with ACC2 selective inhibitory activity. This patent also includes a pharmaceutical composition comprising the compound.

Career Highlights

Kana Kurahashi is associated with Shionogi Company Limited, where she has been instrumental in advancing research and development in her field. Her innovative approach and dedication to her work have established her as a key figure in pharmaceutical inventions.

Collaborations

Kana has collaborated with notable colleagues, including Yoshikazu Sasaki and Yuji Nishiura. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries.

Conclusion

Kana Kurahashi's contributions to the field of pharmaceuticals through her innovative patents highlight her role as a leading inventor. Her work continues to pave the way for advancements in medical science and therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…